Synthetic Design Lab, a San Francisco, CA-based antibody-drug conjugate (ADC) firm advancing its novel SYNTHBODY therapeutic platform towards a spread of most cancers indications, raised $20M in funding.
The spherical was led by Playground World and Godfrey Capital.
The corporate intends to make use of the funds to maneuver its first therapeutic into medical trials subsequent yr.
Led by CEO Daniel S. Chen, and CSO Ramesh Baliga, Ph.D., Artificial Design Lab empowers antibody-drug conjugates (ADCs) with its SYNTHBODY therapeutic platform, which is engineered to optimize focused payload supply, probably enhancing upon the efficacy, security, and general versatility of earlier ADCs.
Daniel S. Chen, M.D., Ph.D., is a number one physician-scientist and pioneer within the fields of most cancers immunotherapy and protein engineering. A co-author of the famend Most cancers Immunity Cycle scientific framework, Dr. Chen spent over a decade at Genentech the place he centered on the event of immune modulators, anti-angiogenics, and ADCs as focused therapies. This included main medical growth for atezolizumab (TECENTRIQ®), the primary accepted PD-L1 inhibitor, from pre-IND by medical trials to a number of international approvals. He’s the Immune Engineering Co-Chair of the Society for Immunotherapy of Most cancers (SITC), a founding accomplice at Genesis BioCapital, and sits on the Board of the Protein & Antibody Engineering Summit (PEGS BOSTON 2025).
FinSMEs
